Keywords: promising, ph, ii, data, genzyme/bayer, alemtuzumab, findings

Promising Ph II data for Genzyme/Bayer's alemtuzumab

Article | 27 October 2008

Print This

Findings from a mid-stage study suggest that leukemia drug Campath (alemtuzumab) can have a large and durable impact on patients ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in